N',N''''-bis-(4-chloro-phenyl)-N,N'''-hexanediyl-di-guanidine | 47594-51-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N',N''''-bis-(4-chloro-phenyl)-N,N'''-hexanediyl-di-guanidine
• 英文别名: N',N''''-Bis-(4-chlor-phenyl)-N,N'''-hexandiyl-di-guanidin；2-[6-[[Amino-(4-chloroanilino)methylidene]amino]hexyl]-1-(4-chlorophenyl)guanidine
• CAS: 47594-51-4
• 化学式: C₂₀H₂₆Cl₂N₆
• 分子量: 421.373
• InChiKey: AWKRYULSDGIRGX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  28
• 可旋转键数：
  11
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  101
• 氢给体数：
  4
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  1,6-己二异氰酸脂 在 氨 、 mercury(II) oxide 作用下， 生成 N',N''''-bis-(4-chloro-phenyl)-N,N'''-hexanediyl-di-guanidine
  参考文献：
  名称：

  850.具有抗菌活性的双双胍

  摘要：

  DOI：

  10.1039/jr9560004422

文献信息

• CURABLE COMPOSITION AND CURED PRODUCT THEREOF
  申请人：Kaneka Corporation

  公开号：EP2338938A1

  公开（公告）日：2011-06-29

  The present invention aims to provide a curable composition without adverse effects on the environment, which exhibits excellent curability without containing a toxic organotin curing catalyst, and gives a cured product that does not have discoloration and cracks on the surface thereof even after being exposed to the atmosphere and ultraviolet light for a long time. The present invention also aims to provide the cured product. The curable composition comprises: (A) an organic polymer having a reactive silyl group; (B) a guanidine compound having a specific structure; and (C) a phosphorus compound that has an aryl group, has a phosphorus atom with an oxi.dation number of +5, and has a melting point of 23°C or higher.

  本发明的目的是提供一种对环境无不良影响的固化组合物，该组合物不含有毒的有机锡固化催化剂，具有优异的固化性能，即使长期暴露在大气和紫外线下，其表面也不会出现变色和裂纹。本发明还旨在提供固化产品。固化组合物包括：(A) 具有活性硅基的有机聚合物；(B) 具有特定结构的胍化合物；(C) 具有芳基、磷原子的阳离子数为 +5、熔点为 23℃或更高的磷化合物。
• COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATMENT OF PROTEINOPATHIES
  申请人：Washington University

  公开号：US20210228591A1

  公开（公告）日：2021-07-29

  The present disclosure relates generally compositions and methods of using the same for the treatment of proteinopathies (e.g. Alpha-1-antitrypsin deficiency, Non-alcoholic fatty liver disease, Alzheimer's disease, Parkinson's disease, Amyotrophic Lateral Sclerosis, and Huntington's disease) with one or more proteotoxicity reducing agents.
• US8853309B2
  申请人：——

  公开号：US8853309B2

  公开（公告）日：2014-10-07
• [EN] COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATMENT OF PROTEINOPATHIES<br/>[FR] COMPOSITIONS ET PROCÉDÉS D'UTILISATION DE CELLES-CI POUR LE TRAITEMENT DE PROTÉINOPATHIES
  申请人：UNIV WASHINGTON

  公开号：WO2019204764A1

  公开（公告）日：2019-10-24

  The present disclosure relates generally compositions and methods of using the same for the treatment of proteinopathies (e.g. Alpha-1-antitrypsin deficiency, Non-alcoholic fatty liver disease, Alzheimer's disease, Parkinson's disease, Amyotrophic Lateral Sclerosis, and Huntington's disease) with one or more proteotoxicity reducing agents.
• 850. Bisdiguanides having antibacterial activity
  作者：F. L. Rose、G. Swain

  DOI：10.1039/jr9560004422

  日期：——